References

Obeng, S., Wilkerson, J. L., Leon, F., Reeves, M. E., Restrepo, L. F., et al. (2021). Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for μ-Opioid Receptor and Morphine-Like Discriminative-Stimulus Effects in Rats. Journal of Pharmacology and Experimental Therapeutics, 376(3), 410–427.

In rats, 7-OH fully substituted for morphine in drug-discrimination assays while mitragynine did not, indicating 7-OH produces morphine-like subjective effects. Direct evidence that 7-OH carries higher abuse-liability signal than mitragynine.

Chakraborty, S., Uprety, R., Daibani, A. E., Rouzic, V. L., Hunkele, A., et al. (2021). Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Indolenine Alkaloids from Kratom. ACS Chemical Neuroscience, 12(14), 2661–2678.

Characterized minor kratom alkaloids beyond mitragynine and 7-OH, including speciogynine and speciociliatine, and clarified that the receptor-binding signature attributed to 'kratom' is largely driven by 7-OH rather than the alkaloid mixture as a whole.

Kamble, S. H., Sharma, A., King, T. I., León, F., McCurdy, C. R., & Avery, B. A. (2020). Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom). Xenobiotica.

Identified CYP3A4 as the principal enzyme converting mitragynine to 7-OH in human liver microsomes, and mapped additional Phase I metabolites. Implies that CYP3A4 inhibitors (grapefruit juice, ketoconazole, ritonavir) and inducers may meaningfully alter 7-OH exposure from kratom.

Garcia-Romeu, A., Cox, D. J., Smith, K. E., Dunn, K. E., & Griffiths, R. R. (2020). Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence, 208, 107849.

National US online survey (n≈2,800). Most respondents were middle-aged, employed, and used kratom primarily for pain (~91%), anxiety/depression (~67%), or to reduce opioid use (~41%). Withdrawal severity self-reported as mild-to-moderate. Often cited to argue real-world kratom use looks different from regulatory characterizations.

Kruegel, A. C., Uprety, R., Grinnell, S. G., Langreck, C., Pekarskaya, E. A., et al. (2019). 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. ACS Central Science, 5(6), 992–1001.

Demonstrated that mitragynine is metabolized to 7-OH in vivo via CYP3A4, and that blocking this conversion eliminates kratom's analgesic effect in mice. Foundational evidence that 7-OH — not mitragynine — does the opioid work after kratom ingestion. Central to the 'natural vs. concentrated/semi-synthetic' regulatory argument.

Hemby, S. E., McIntosh, S., Leon, F., Cutler, S. J., & McCurdy, C. R. (2019). Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addiction Biology, 24(5), 874–885.

Rats self-administered 7-OH at rates comparable to morphine, while mitragynine did not maintain self-administration. Direct preclinical evidence that 7-OH — isolated from the kratom alkaloid matrix — has abuse liability in the same range as classical opioids.

Coe, M. A., Pillitteri, J. L., Sembower, M. A., Gerlach, K. K., & Henningfield, J. E. (2019). Kratom as a substitute for opioids: results from an online survey. Drug and Alcohol Dependence, 202, 24–32.

Among self-reported kratom users with prior opioid use, the majority described kratom as a substitute that reduced or eliminated opioid use without the same withdrawal severity. Industry-adjacent funding — note this when weighing against independent abuse-liability data.

Post, S., Spiller, H. A., Chounthirath, T., & Smith, G. A. (2019). Kratom exposures reported to United States poison control centers: 2011–2017. Clinical Toxicology, 57(10), 847–854.

US poison center calls involving kratom rose ~52-fold from 2011 to 2017 (13 → 682 annual exposures). Most exposures were in adults, with agitation, tachycardia, drowsiness, and seizures as common features; ~32% required medical-facility admission. Quantifies the rising acute-harm signal that preceded the 7-OH-specific product wave.

Eggleston, W., Stoppacher, R., Suen, K., Marraffa, J. M., & Nelson, L. S. (2019). Kratom Use and Toxicities in the United States. Pharmacotherapy, 39(7), 775–777.

Case series including kratom-associated deaths in upstate New York. Several decedents had only kratom alkaloids on toxicology, undermining the common claim that kratom-attributed deaths always involve other substances.

Grundmann, O. (2017). Patterns of Kratom use and health impact in the US—Results from an online survey. Drug and Alcohol Dependence, 176, 63–70.

Earliest large US survey of kratom users (n≈8,000). Established the demographic baseline (predominantly white, middle-aged, college-educated, employed) that subsequent epidemiology has largely confirmed.

Kruegel, A. C., Gassaway, M. M., Kapoor, A., Váradi, A., Majumdar, S., Filizola, M., Javitch, J. A., & Sames, D. (2016). Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. Journal of the American Chemical Society, 138(21), 6754–6764.

Established 7-OH as a partial μ-opioid agonist with binding affinity roughly 13× morphine and ~46× mitragynine, while showing markedly reduced β-arrestin-2 recruitment compared to morphine. Source of the potency ratios cited across consumer and regulatory coverage.

Váradi, A., Marrone, G. F., Palmer, T. C., Narayan, A., Szabó, M. R., et al. (2016). Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2. Journal of Medicinal Chemistry, 59(18), 8381–8397.

Synthesized pseudoindoxyl derivatives of mitragynine and 7-OH that combined μ-agonism with δ-antagonism and did not recruit β-arrestin-2 — a chemical scaffold that produced analgesia in mice without the respiratory depression and tolerance profile of morphine. The biased-agonism rationale used to argue 7-OH is 'safer' than classical opioids traces to this paper.

Trakulsrichai, S., Sathirakul, K., Auparakkitanon, S., Krongvorakul, J., Sueajai, J., et al. (2015). Pharmacokinetics of mitragynine in man. Drug Design, Development and Therapy.

First human pharmacokinetic data on mitragynine in chronic kratom users. Established a long terminal half-life (≈24 hours) and confirmed dose-proportional plasma exposure — relevant context for the duration-of-action claims around 7-OH-rich products.

Singh, D., Müller, C. P., & Vicknasingam, B. K. (2014). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 139, 132–137.

Field study of long-term Malaysian kratom users found a dose-dependent withdrawal syndrome (muscle aches, insomnia, irritability, craving) closely paralleling opioid withdrawal. Establishes that physical dependence develops with chronic traditional-leaf use, before considering the additional risk profile of 7-OH-concentrated products.

Matsumoto, K., Horie, S., Ishikawa, H., Takayama, H., Aimi, N., Ponglux, D., & Watanabe, K. (2004). Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sciences, 74(17), 2143–2155.

First demonstration that 7-OH given orally to mice produced antinociception comparable to morphine at far lower doses, establishing 7-OH (not mitragynine) as the principal driver of kratom's opioid-like analgesia.

Eastlack, S. C., Cornett, E. M., & Kaye, A. D. (2020). Kratom—Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review. Pain and Therapy, 9(1), 55–69.

Pain-medicine-oriented review of kratom's mechanism, dose-response, and clinical risk profile. Frames the therapeutic-vs.-abuse trade-off in the language clinicians use when patients ask about kratom or 7-OH for chronic pain.

Veltri, C., & Grundmann, O. (2019). Current perspectives on the impact of Kratom use. Substance Abuse and Rehabilitation, 10, 23–31.

Synthesizes survey and clinical data on US kratom users circa 2019: most users self-report self-treatment of pain, anxiety, or opioid withdrawal rather than recreational use, with adverse events concentrated in concomitant-substance and high-dose extract cases.

Kruegel, A. C., & Grundmann, O. (2018). The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology, 134(Pt A), 108–120.

The most-cited integrative review of kratom pharmacology in the modern literature. Frames mitragynine as a low-efficacy partial μ-agonist whose effects in users are mediated largely by metabolic conversion to 7-OH, and argues the alkaloid mix has a different abuse-liability profile than concentrated 7-OH products.

Henningfield, J. E., Fant, R. V., & Wang, D. W. (2018). The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulating products sold in the United States. Psychopharmacology, 235(2), 573–589.

Industry-funded eight-factor analysis arguing kratom leaf does not meet the threshold for Schedule I scheduling; explicitly distinguishes leaf from concentrated 7-OH products. Cited heavily by the American Kratom Association — flagged here so the funding source is transparent to readers comparing it against independent assessments.

Cinosi, E., Martinotti, G., Simonato, P., Singh, D., Demetrovics, Z., et al. (2015). Following 'the Roots' of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries. BioMed Research International.

Documents the global trajectory from traditional Southeast Asian leaf use to Western recreational/extract markets. Important context for why concentrated 7-OH products are a recent phenomenon distinct from traditional kratom use.

Prozialeck, W. C., Jivan, J. K., & Andurkar, S. V. (2012). Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. Journal of the American Osteopathic Association, 112(12), 792–799.

Early clinician-facing review establishing the dose-dependent stimulant-then-opioid pattern of kratom and flagging dependence risk. Useful as historical baseline for what was known pre-2016 versus what has been added by 7-OH-specific research.

U.S. Food and Drug Administration (2025). FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers..

July 29, 2025 FDA press release recommending DEA place 7-hydroxymitragynine in Schedule I of the Controlled Substances Act. The recommendation explicitly targets concentrated/semi-synthetic 7-OH products — not natural kratom leaf. DEA has final scheduling authority and must complete a rulemaking process including public comment before any action is finalized.

U.S. Food and Drug Administration (2025). FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine..

Companion action to the July 2025 scheduling recommendation — FDA issued warning letters to seven companies marketing 7-OH products, citing unapproved new drug and misbranding violations. The enforcement coupling (scheduling recommendation + warning letters) signaled FDA intent to act on 7-OH even before DEA scheduling finalizes.

U.S. Food and Drug Administration (2025). 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data..

The scientific dossier FDA released alongside the July 2025 scheduling recommendation. Compiles pharmacology, abuse-liability, and adverse-event data assembled internally by FDA; the document DEA is weighing in its rulemaking review.

Olsen, E. O., O'Donnell, J., Mattson, C. L., Schier, J. G., & Wilson, N. (Centers for Disease Control and Prevention) (2019). Notes from the Field: Unintentional Drug Overdose Deaths with Kratom Detected — 27 States, July 2016–December 2017. Morbidity and Mortality Weekly Report (MMWR), 68(14), 326–327.

CDC analysis of 152 overdose deaths with kratom detected, 91 of which had kratom listed as a cause. Most also involved fentanyl or other opioids, but seven decedents tested positive only for kratom — the most-cited federal data point for kratom-only fatal toxicity.

Anwar, M., Law, R., & Schier, J. (Centers for Disease Control and Prevention) (2016). Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to Poison Centers — United States, 2010–2015. Morbidity and Mortality Weekly Report (MMWR), 65(29), 748–749.

CDC-published surveillance showing a tenfold increase in kratom poison-center calls from 2010 to 2015. The first federal-source quantification of rising US kratom exposure that DEA cited in its 2016 scheduling notice.

U.S. Drug Enforcement Administration (2016). Schedules of Controlled Substances: Temporary Placement of Mitragynine and 7-Hydroxymitragynine into Schedule I..

DEA's August 2016 Notice of Intent to emergency-schedule mitragynine and 7-OH as Schedule I. Cited the CDC poison-center data and 15 deaths attributed to kratom. Anchor document for understanding the federal scheduling history.

U.S. Drug Enforcement Administration (2016). Withdrawal of Notice of Intent to Temporarily Place Mitragynine and 7-Hydroxymitragynine into Schedule I..

DEA withdrew the emergency scheduling proposal six weeks later after ~23,000 public comments and Congressional pushback, deferring the decision pending FDA review. The first time DEA had reversed an emergency scheduling action.